|Articles|January 1, 2006

Pharmacy Times

  • Volume 0
  • 0

US COURT UPHOLDS MAINE'S PBM DISCLOSURE LAW

A federal appeals court in Maine hasshot down efforts by the pharmacy benefitsmanagement (PBM) industry tooverturn legislation in that state requiringPBMs to disclose their businesspractices. The ruling will help to "pavethe way for more states to enact consumerprotections against PBM businesspractices," officials at the NationalCommunity Pharmacists Association(NCPA) said.

The Maine statute, one of a growingnumber of state laws requiring PBMs todisclose payment arrangements thatthey make with pharmaceutical manufacturers,had been challenged asunconstitutional by the PharmaceuticalCare Management Association (PCMA)—an industry group representing PBMs.

In upholding the Maine law, the federalcourt scored "an important victory forconsumers," by making it clear that"states have the right to monitor andregulate the business practices of thesedrug middlemen," NCPA Executive VicePresident Bruce Roberts said.

"The only people who are benefitingfrom the PBMs are the people who runthe PBMs," said Roberts. "It's little wonderthat PCMA and the large PBMs itrepresents don't want to reveal howthey are doing business."

In addition to Maine, PBM reformmeasures have been enacted in NorthDakota, Georgia, Maryland, SouthDakota, and the District of Columbiaand are being considered in a numberof other states.

Articles in this issue

almost 21 years ago

High Alert Insulin Bin

almost 21 years ago

Hydase (hyaluronidase injection, USP)

almost 21 years ago

Humira (adalimumab)

almost 21 years ago

INVANZ (ertapenem for injection)

almost 21 years ago

Compounding HOTLINE

almost 21 years ago

Can You Read These Rxs?

Related to this article

Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.